Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs KKR & Co Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.04 (market cap $39.89B), while KKR & Co Inc trades at $96.87 (market cap $87.04B). The key difference: KKR & Co Inc is far larger — about 2.2× Alnylam Pharmaceuticals, Inc.'s market cap, and KKR & Co Inc pays a 0.77% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KKR | |
|---|---|---|
Market Cap | $39.89B | $87.04B |
Sector | Health | Financials |
52-Week High | $491.22 | $152.16 |
52-Week Low | $278.09 | $83.88 |
Enterprise Value | $38.15B | $12.56B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
KKR trades at $96.94, up 0.7% today, with a bullish technical outlook supported by moving averages and near-term resistance at $97. Recent earnings beat expectations in Q1 2026, and the firm is expanding through strategic acquisitions like the $4.2 billion EDF power solutions deal and a $1.3 billion renewable energy platform in South Korea. Strong analyst sentiment includes 24 buy ratings and a consensus price target of $127.71, indicating significant upside potential.
The outlook for KKR is positive, driven by robust monetization activity, strategic growth initiatives, and a favorable analyst consensus. Key risks include volatile cash flows from operations, high leverage with long-term debt of $49.91 billion, and dependence on private market conditions. Investors should weigh the growth opportunities against these financial and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
